b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29279522</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>02</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>02</Month>\n            <Day>06</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1349-3299</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>59</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>Jan</Month>\n                        <Day>27</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>International heart journal</Title>\n                <ISOAbbreviation>Int Heart J</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>126-135</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1536/ihj.16-482</ELocationID>\n            <Abstract>\n                <AbstractText>We assessed the efficacy and safety of direct oral anticoagulants (DOACs) for the treatment of deep venous thrombosis (DVT) in the chronic phase through comparison with conventional warfarin therapy.A total of 807 consecutive patients who were diagnosed with having DVT in the chronic phase were included (484 patients to warfarin therapy and 323 patients to DOAC therapy). The condition of leg veins was assessed 3 to 6 months after starting the therapies by ultrasound examination. Major bleeding and mortality during the therapies were followed-up.There was no significant difference between the two groups in the thrombosis improvement rate (DOAC group: 91.2% versus warfarin group: 88.9%). There was no significant difference between the two groups in major bleeding (DOAC group: 1.8% versus warfarin group: 1.8%). In patients with active cancer, the DOAC group had a borderline higher thrombosis improvement rate than the warfarin group (92.1% versus 80.0%, P = 0.05). The proportion of major bleeding in the patients with active cancer was slightly higher in the warfarin group than in the DOAC group (4.3% versus 2.8%; P = 0.71). Active cancer was not an independent risk factor for major bleeding and recurrence in the DOAC group (OR 2.68, 95% CI 0.51-14.1; P = 0.24 and OR 0.65, 95% CI 0.20-2.07; P = 0.47).In treatment using oral anticoagulants for DVT in the chronic phase, DOACs exhibited equal efficacy and safety as warfarin did. Particularly DOACs appear to be an attractive therapeutic option for cancer-associated DVT in chronic phase, with relatively low anticipated rates of recurrence and major bleeding.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Wakakura</LastName>\n                    <ForeName>Shingo</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hara</LastName>\n                    <ForeName>Fumihiko</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fujino</LastName>\n                    <ForeName>Tadashi</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hamai</LastName>\n                    <ForeName>Asami</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ohara</LastName>\n                    <ForeName>Hiroshi</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kabuki</LastName>\n                    <ForeName>Takayuki</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Harada</LastName>\n                    <ForeName>Masahiko</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ikeda</LastName>\n                    <ForeName>Takanori</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular Medicine, Toho University Faculty of Medicine.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D064888">Observational Study</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>27</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Japan</Country>\n            <MedlineTA>Int Heart J</MedlineTA>\n            <NlmUniqueID>101244240</NlmUniqueID>\n            <ISSNLinking>1349-2365</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000991">Antithrombins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>3Z9Y7UWC1J</RegistryNumber>\n                <NameOfSubstance UI="C522181">apixaban</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>5Q7ZVV76EI</RegistryNumber>\n                <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>I0VM4M70GC</RegistryNumber>\n                <NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>NDU3J18APO</RegistryNumber>\n                <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000991" MajorTopicYN="N">Antithrombins</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName>\n                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Cancer</Keyword>\n            <Keyword MajorTopicYN="N">Thrombosis dissolution</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>2</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>28</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29279522</ArticleId>\n            <ArticleId IdType="doi">10.1536/ihj.16-482</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'